Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet

Mania Amiri 1, Masoumeh Golsorkhtabaramiri 1, Sedigheh Esmaeilzadeh 1*, Faeze Ghofrani 1, Ali Bijani 2, Leila Ghorbani 3, Moloud Agajani Delavar 1

1- Fatemezahra Infertility and Reproductive Health Research Center, Babol University of Medical Sciences, Babol, Iran
2- Non-Communicable Pediatric Disease Research Center, Amirkola Children’s Hospital, Babol University of Medical Sciences, Babol, Iran
3- Obstetrics and Gynecology Department, Babol University of Medical Sciences, Babol, Iran

Abstract

Background: This study was designed to investigate the effect of metformin and flutamide alone or in combination with anthropometric indices and laboratory tests of obese/overweight PCOS women under hypocaloric diet.

Methods: This single blind clinical trial was performed on 120 PCOS women. At the beginning, hypocaloric diet was recommended for the patients. After one month while they were on the diet, the patients were randomly divided in 4 groups; metformin (500 mg, 3/day), flutamide (250 mg, 2/day), combined, metformin (500 mg, 3/day) with flutamide (250 mg, 2/day) and finally placebo group. The patients were treated for 6 months. Anthropometric indices and laboratory tests (fasting and glucose-stimulated insulin levels, lipid profile and androgens) were measured. A one-way ANOVA (Post Hoc) and paired t-test were performed to analyze data. A p ≤ 0.05 was considered statistically significant.

Results: After treatment, reduction in weight, BMI, hip circumference was significantly greater in the metformin group in comparison to other groups (p<0.05). In addition, the fasting insulin was significantly greater in metformin group and flutamide group in comparison to metformin+flutamide and placebo groups after treatment (p<0.05). Within groups, insulin level showed significant changes (before and after treatment) in metformin+flutamide group and LDL reduction was significant in flutamide group before and after treatment. Post hoc tukey and two-tailed with p<0.05 were used to define statistical significance.

Conclusion: Using combination of metformin and flutamide improves anthropometric indices and laboratory tests in obese/overweight PCOS women under hypocaloric diet.

Keywords: Body weight, Flutamide, Metformin, Polycystic ovary syndrome.


Introduction

Polycystic ovarian morphology is displayed on ultrasound imaging in approximately 11.9±2.4 of women (1). The most common features of PCOS are hyperandrogenism, unovulation, infertility and weight gain. More than 50% of PCOS patients are obese (2). These women are at the risk of diabetes, atherosclerosis, and cardiovascular diseases (1, 3). Since obesity is the most common cause of insulin resistance and hyperandrogenism, weight reduction might be the first
recommendation for PCOS women (4, 5). Many researchers introduced hypocaloric diet as an op-
erant treatment for weight loss and improvement of fertility in the overweight/obese PCOS women. However, only 5-10% weight loss has a useful ef-
fect on insulin resistance and cardiovascular he-
modynamic function (4-6).

Weight loss up to 5-7% during 6 month can re-
store ovulation and fertility in more than 75% of
women (5). Weight loss induced by hypocaloric
diet was intensified by treatment with metformin
(7, 8). Hyperinsulinemia has a role in anovulation.

In addition, several studies have shown weight
loss reduces the severity of insulin resistance (9,
10). Treatment with insulin sensitizer agents may
also alter endocrine imbalance, improves ovula-
tion and fertility (11). Even some researchers rec-
commended 3 months of pretreatment with met-
formin for obese women (12, 13). Pasquali et al.
showed hirsutism and irregular menses in PCOS
patients who received metformin were significant-
ly improved in comparison to placebo group and
also hypocaloric diet reduced BMI and waist cir-
cumference (WC) in PCOS patients as well as the
controls. In both groups, treatment with metfor-
min reduced weight and BMI significantly (14).
Treatment with metformin reduces LH and andro-
gens level and restores regular menses and ovula-
tion (1, 2). Also, treatment with the antiandrogen
drugs such as flutamide reduced hirsutism and
abdominal fat (15). In Sahin et al.’s study, treat-
ment with metformin improved insulin resistance
and reduced androgen levels. However, flutamide
only reduces androgen levels without improve-
ment of insulin resistance in non-obese patients
(16). Gambineri et al. studied 40 obese PCOS pa-
tients during 6 months and showed that hypo-
caloric diet with metformin or flutamide alone or
in combination had a significant effect on body
lipid distribution, androgen levels, hirsutism and
menses (17). Gambineri in another study evaluat-
ed 80 women within 12 months and showed the
benefits of long term treatment with metformin
and flutamide and their compounds in obese
PCOS patients under hypocaloric diet. In his
study, flutamide reduced visceral fat, androgen
levels and lipid profile after 12 months and im-
proved glucose tolerance value in comparison to
placebo and metformin though there was no syn-
ergistic effect in patients who simultaneously re-
ceived the combination of the two drugs (18).
However, the other study showed that hypocaloric
diet with metformin or flutamide alone or in com-
bination had a better therapeutic effect (14).

More recently, literature revealed contradictory
findings about adding medicine to the diet and
especially there has been little agreement on the
beneficial effects of polytherapy; hence, in this
study, an attempt was made to address the follow-

ing question:

Do metformin and flutamide alone or combina-
tion of both improve anthropometric indices and
laboratory tests in overweight and obese PCOS
patients under hypocaloric diet?

Methods

First, 156 overweight and obese infertile PCOS
women entered this single blind clinical trial
(Clinical trial registration number: IRCT13880
7279760N3, May 21, 2010). These patients were
referred to our PCOS clinic (Fatemezahra Infert-
ility and Reproductive Health Research Center)
in Babol (north of Iran) in 2009. Out of them, 117
women were recruited and randomized to the
treatment after considering exclusion and inclu-
sion criteria.

This study was approved by the ethical commit-
tee of Babol University of Medical Science. At
the beginning, all participants signed an informed
consent and entered the study. Inclusion criteria
included all PCOS women of 18-40 years of age,
body mass index (BMI) >19 and <35 kg/m² and
waist circumference of at least 88 cm (19). The
diagnosis of PCOS was determined by presence of
two or more following conditions of Rotterdam
criteria; oligo-ovulation or anovulation (manifest-
ed as oligomenorrhea or amenorrhea), hyperan-
drogenemia (elevated levels of circulating andro-
gens), hyperandrogenism (clinical manifestations
of androgens excess) and polycystic ovaries de-
tected by ultrasonography (20). Exclusion criteria
were any drug consumers (hormonal and metfor-
min) or cases who tried weight loss in 3 recent
months, cases with hyperprolactinemia, cushing
syndrome, late onset congenital adrenal hyper-
plasia, thyroid dysfunction, diabetes, cardiovascular,
renal and liver diseases, pregnancy and also
athletes. They were advised to use barrier methods
dof contraception throughout the study.

Participants: Before the initiation of the study,
the patients underwent the physical examination
focused on anthropometric indices (weight, BMI,
waist and hip circumferences and hirsutism). The
clinical examination focused on the evaluation of
anthropometric and parametric values (height,
weight and waist circumference) and also hirsu-
tism using the Ferriman-Gallwey score (21). BMI was calculated by weight/height² (kg/m²). Waist circumference was obtained as the minimum value between the iliac crest and the lateral costal margin, whereas hip circumference was determined as the maximum value over the glottal region to cm. Waist and hip circumferences were measured to the nearest centimeter with a soft tape (cm) according to World Health Organization (WHO) criteria. Before the study, the baseline values of anthropometric parameters were measured. No significant differences were shown in the values.

Hormonal and metabolic determinations included the evaluation of circulating concentrations of free and total testosterone, dehydroepiandrosterone sulfate (DHEA-S), sex hormone-binding globulin (SHBG), triglyceride (TG), total and high-density lipoprotein (HDL) and Low-density (LDL) cholesterol and triglycerides (TG) in fasting blood samples. Also, fasting glucose test, 2-hour oral glucose tolerance test (OGTT) with 75 gr glucose (Parsazmoon Co, Iran) and fasting Insulin test were administered. All blood tests were performed, regardless of the menstrual cycle, at baseline and after 6 months. A qualified laboratory examined the blood samples (at baseline and the following 6-month reevaluation) through the same methods and materials. First, the baseline values of experiments were analyzed. It should be noted that no significant differences were seen in the anthropometric indices and laboratory tests.

To eliminate the confounding effect of diet, all patients received a standardized hypocaloric diet containing 1200-1400 kcal/day from a research dietitian. The diet consisted of 50% carbohydrates, 30% proteins and 20% fat prescribed by the same dietician attending our division, who calculated the dietary energy composition by subtracting at least 500 kcal from the usual energy intake of an individual. The data were gathered by means of a questionnaire. The final composition of the diets ranged between 1200 and 1400 kcal/d. It should be noted that all women were visited monthly for compliance with both dietary and pharmacological treatments. Diet was evaluated by the dietician at each monthly visit, according to previously defined criteria providing quantitative information on daily energy intake and composition of the diet consumed during the previous month. There was a strong reason to initiate the hypocaloric diet before treatment with medicine; all patients equally underwent the similar diet as the only impressive element without any medication intervention. Furthermore, patients were checked for their usual physical activity throughout the treatment by the standard physical activity questionnaire (the Persian version with high validity) before, 3 months following and at the end of the study (21, 22).

Randomization and intervention: From total of 156 overweight or obese PCOS women, 117 women were recruited and randomized to the treatment (Figure 1). Following one month of diet, the participants were visited again. While continuing dietary treatment, the patients who had anthropometric indices and the recording of all preliminary laboratory tests, were randomly divided in 4 groups including, 1: metformin hydrochloride (Tablet, 500 mg, Tehran-shimi Co, Tehran, Iran), orally, 3/day, 2: flutamide-BIOSYN (Tablet, 250 mg, Sobhan Co, Tehran, Iran), 2/day, 3: metformin 500 mg, 3/day+ flutamide 250 mg, 2/day and 4: placebo group. Patients were randomly assigned to groups to receive the drugs (active or placebo) using a computer generated sequence concealed from the study participants and then allocation sequence was done by a third party. Fatemehzahra Investigation Pharmacy transferred metformin, flutamide and placebo capsules with appropriate dose and the same color, then packed and labeled them according to subject number. The patients were blinded to the treatment. All subjects were given a 1-month supply of capsules and they returned for monthly visits. Also, to evaluate compliance with medications and to assess the side effects, patients were visited monthly. To evaluate the liver and renal toxicity at the beginning which were probably the results of medicines, renal and liver functional tests were requested and repeated every 2 months. Moreover, the remaining capsules were counted and a new supply of capsules was given to the patients. The patients were reviewed and recommended to stay on the diet and contraception.

Finally, at the end of the sixth month of treatment, physical examination focusing on anthropometric indices and all preliminary laboratory tests were done again and hirsutism was reevaluated. The same researcher performed all these assessments. All patients underwent anthropometric, hormonal and metabolic evaluation at baseline and 6 months following.

**Statistical Analysis:** Statistical evaluations were performed by running SPSS software package (SPSS Inc., Chicago, IL, USA) on a personal
computer. The sample size was calculated by G*power software and Set $\alpha$ error prob to 0.05, Power to 0.80. The values in ANOVA had normal distribution and the variances of assumed variables were equal. The measures were reported as mean±SD.

Paired t-test was performed to estimate the within-group modification (before and after treatment at each time point). A one-way ANOVA (Post Hoc) was applied to compare values amongst the four groups at each time point (baseline, 6 months following), whereas tukey test was applied to find differences amongst the groups. The $p \leq 0.05$ were used to define statistical significance.

**Results**

Out of 156 PCOS patients who were eligible, 39 women were excluded; 32 women had no inclusion criteria, 6 women declined to participate and one woman met the exclusion criteria. 117 women were randomized in 4 groups; 28 women were allocated to receive metformin, 28 received flutamide (1 woman had no contribution) and 31 women received metformin+flutamide (1 woman had no contribution) and 27 women received placebo. Out of the metformin group, 3 women (1 woman for high transaminase level and 2 women for refusing to follow up), from the flutamide group, one woman for wrong use of medicine,
were lost to follow up. Also, from the metformin+flutamide group, 4 women (2 women for the high transaminase level, 1 for refusing the follow up and one woman for the wrong use of medicine) and from placebo group, one woman was lost to follow up (for changing the place of living). Finally, 25 women in the metformin group, 27 in the flutamide group, 27 in the metformin+flutamide group and 26 in the placebo group were analyzed. Nobody was excluded from analysis (Figure 1). Their mean age was 25.6±4.02 and mean weight was 75.5±9.82 kg. No significant difference was seen in the anthropometric indices and laboratory tests in baseline values.

**Comparing changes within the four groups (before and after treatment):** Table 1 summarizes the anthropometric indices and laboratory test changes (before and after treatment) within the four groups. To determine the within-group changes, paired t-test was applied.

As well as placebo, the groups treated with metformin, flutamide, and metformin+flutamide showed significant reduction in all anthropometric indices following 6 months in comparison to their baseline except HC in flutamide group which was not significant.

In the glucose profile, the FBS initially demonstrated significant reduction within metformin+flutamide group and then within placebo group before and after treatment, respectively (p<0.001) (p<0.05). However, the fasting insulin showed no further modification after treatment compared to baseline except within metformin+flutamide group (p<0.001).

In the lipid profile, LDL had significant reduction in all groups except metformin+flutamide following the treatment compared to baseline (metformin; p<0.001), (flutamide; p<0.01) (placebo; p<0.05).

In sex hormones, all groups demonstrated no significant reduction except DHEA (S) in which significant reduction was seen in metformin+flutamide group and also placebo after treatment compared to the baseline.

The menstrual pattern of our patients showed no significant differences before and after treatment.

**Comparing amongst the four groups: The anthropometric indices and laboratory tests of four groups after treatment are summarized in table 2.** There were no significant differences in the baseline values in our study. In anthropometric indices, significantly greater reductions were observed in BMI, WC and HC in the metformin group after treatment in comparison to other groups (p<0.001). In sugar profile, the post treatment fasting blood sugar and fasting insulin were diminished.

### Table 1. Changes in anthropometric indices and laboratory tests within the 4 groups under study (before and after treatment)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Metformin (n=25)</th>
<th>Flutamide (n=27)</th>
<th>Metformin+Flutamide (n=27)</th>
<th>Placebo (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BMI (Kg/m²)</strong></td>
<td>4.2±2.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.8±1.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3±1.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.9±1.9&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>WC (cm)</strong></td>
<td>10.9±6.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.6±6.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.4±5.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8.4±5.9&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>HC (cm)</strong></td>
<td>10.4±7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.2±8.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.1±7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.5±7.8&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>W/H</strong></td>
<td>0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.05&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.05&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Hirsutism score</strong></td>
<td>2.5±3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.8±2.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.3±11.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.7±7&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>FBS (mg/dl)</strong></td>
<td>2.6±12.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.8±10.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.9±10&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-4.8±11.4&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>OGTT (2 hr) (mg/dl)</strong></td>
<td>-0.28±25.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.1±25.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10±38.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10.6±42.1&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Fasting Insulin (pM/l)</strong></td>
<td>1.4±11.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-1.4±11.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10.0±8.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.2±12.4&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>TG (mM/l)</strong></td>
<td>6.4±48&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.84±2.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.1±4.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7±65.7&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Total Cholesterol (mM/l)</strong></td>
<td>10.1±24.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>21.3±33.7&lt;sup&gt;b&lt;/sup&gt;</td>
<td>8.2±57.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>19.7±31&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>HDL (mM/l)</strong></td>
<td>-1.2±12&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-3.8±14.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4.2±11.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-3.8±11.3&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>LDL (mM/l)</strong></td>
<td>10.9±29.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>19.9±30.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>-1±58.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.7±27.2&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Total testosterone (mM/l)</strong></td>
<td>0.4±0.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.2±0.47&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.4±0.6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.7&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Free testosterone (pM/l)</strong></td>
<td>0.3±1.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.3±3.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.6±1.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.5±3.2&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>DHEAS (mM/l)</strong></td>
<td>2.7±71.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>31.2±126.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>42.3±82.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>38.2±93.6&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>SHBG (mM/l)</strong></td>
<td>1.5±18.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-5.5±47.8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.63±14.6</td>
<td>2.8±16.3&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

**Table 1.**

- Changes (post treatment value- pre treatment value) was significant at p<0.005; b: Changes (post treatment value- pre treatment value) was significant at p<0.01; c: Changes (post treatment value- pre treatment value) was significant at p<0.001; d: Comparing changes between groups was significant at p<0.05; e: Comparing changes between groups was significant at p<0.001.

1: Ferriman-Gallway score
Table 2. Parametric indices and metabolic parameters of women among the four groups under study

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Groups</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>After treatment Met (n=25)</td>
<td>After treatment Flu (n=27)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.9±5.2*</td>
<td>29.5±4.1*</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>89.4±9.5*</td>
<td>88.19±9.9*</td>
</tr>
<tr>
<td>HC (cm)</td>
<td>110.6±10.8*</td>
<td>110.1±11</td>
</tr>
<tr>
<td>W/H (cm)</td>
<td>0.8±0.1</td>
<td>0.8</td>
</tr>
<tr>
<td>Hirsutism score 1</td>
<td>7.08±3.8*</td>
<td>7.5±2.5*</td>
</tr>
<tr>
<td>FBS (mg/dl)</td>
<td>81.9±8.1</td>
<td>83.7±7.2</td>
</tr>
<tr>
<td>OGGTT (2 hr) (mg/dl)</td>
<td>112.1±30.5</td>
<td>102.56±20.1</td>
</tr>
<tr>
<td>Fasting Insulin (pM/l)</td>
<td>13.7±7.1</td>
<td>14.6±6.2</td>
</tr>
<tr>
<td>TG (mM/l)</td>
<td>122.3±41.1</td>
<td>133.6±72*</td>
</tr>
<tr>
<td>Total Cholesterol (mM/l)</td>
<td>171.3±23.2*</td>
<td>178.5±48*</td>
</tr>
<tr>
<td>HDL (mM/l)</td>
<td>41.3±11.3</td>
<td>43±12.2</td>
</tr>
<tr>
<td>LDL (mM/l)</td>
<td>100.74±19.7*</td>
<td>105.8±32*</td>
</tr>
<tr>
<td>Total testosterone (nM/l)</td>
<td>0.7±0.4*</td>
<td>0.55±0.2</td>
</tr>
<tr>
<td>Free testosterone (pM/l)</td>
<td>2.32±1.3</td>
<td>2.18±1.9</td>
</tr>
<tr>
<td>DHEAS (mM/l)</td>
<td>222.5±129.1</td>
<td>145.46±81.1*</td>
</tr>
<tr>
<td>SHBG (mM/l)</td>
<td>26.9±18.9</td>
<td>41.08±39</td>
</tr>
</tbody>
</table>

Results are expressed as Mean±SD. The values were evaluated with the Post Hoc test; No significant differences among groups in baseline values; Difference by group p<0.05; NS=Non significant >0.05; Met=Metformin; Flu=Flutamide; P=Placebo

* The difference between groups (in a row) is significant
1: Ferriman-Gallway score

significantly in metformin+flutamide group compared to other groups after treatment (p<0.001), while in the lipid profile, metformin+flutamide revealed reduction in TG and placebo reduced LDL significantly after treatment compared to other groups (p<0.001). In sex hormone profiles, the flutamide group was superior to others in reduction of total testosterone (p<0.01) and in the placebo, the reduction of DHEA(S) was observed after treatment (p<0.05) (Table 2).

It should be mentioned that, throughout the study, markers of liver dysfunction such as transaminases and lactate dehydrogenase were checked monthly and they remained unaltered except among 3 women.

Discussion

The result of our study indicates that the use of metformin and flutamide improves anthropometric indices and laboratory tests in obese/overweight PCOS women under hypocaloric diet.

Metformin alone was successful to reduce BMI in PCOS patients. Generally, in obese women with anovulatory infertility, weight loss makes spontaneous ovulation facile and improves the chance of spontaneous conception (24). Those patients who ovulate and conceive while remaining obese will encounter predictable risks during pregnancy and post-pregnancy. Since pre-pregnancy weight loss reduces the incidence of gestational diabetes in these women (25), most therapists encourage PCOS women to reduce weight before pregnancy.

The findings of the current study are consistent with that of Morin-Papunen et al. who found metformin is able to decrease glucose disposal in skeletal muscle (26). Also, a number of studies have found the reduction in weight and BMI by metformin (7, 27, 28), however, there are many conflicting ideas about the effect of metformin on weight and BMI. Tang et al. concluded that metformin treatment is less effective in very obese anovulatory women and a higher dose instead of routinely prescribed doses and a longer duration of therapy are necessary for these patients (29). In addition, Nieuwenhuis-Ruifrok in his systematic review concluded that addition of metformin treatment does not lead to greater weight loss in patients who are on a diet or who follow a lifestyle program (8). A possible explanation for those might
be that regarding our patients' mean BMI (32
\( \text{kg/m}^2 \)), no further doses were needed for them.

Our unanticipated finding shows that the combi-
nation of the two drugs as a part of polytherapy
provides beneficial effects on glucose reduction.
Wadden concluded that more weight loss is
achieved by combination of a lifestyle modifica-
tion program with drug therapy in comparison to a
lifestyle program alone (30). However, in Gambi-
neri et al.’s research hypocaloric diet alone has a
main role in improving insulin resistance and
hyperinsulinaemia. Gambineri also conducted an-
other study on PCOS patients during 12 months
and concluded metformin alone decreased glu-
cose-stimulated insulin but the combination of
both drugs had no additive effect. He explained
that some therapeutic effects would not be present
during the first six months of treatment (18)
though, in this paper this incidence took place
within 6 month.

Our interesting finding was that metformin+
flutamide reduced TG more than other medicines
except hypocaloric diet. This finding is not in
agreement with Gambineri et al.’s findings which
showed none of the active treatment groups dif-
fered in changes of lipid concentrations after 6
months of treatment, whereas they observed a
greater reduction in LDL cholesterol after 12
months in the metformin+flutamide group. Maybe
the initial results of LDL reduction in our study
relates to the lesser weights of our patients in
comparison to the patients in their study (18).

One of the limitations of our study was small
sample size of the obese women which over-
lapped with overweight women, so the effect of
medicine on them versus overweight women
could not be evaluated.

In our study, the menstrual pattern of our pa-
tients showed no significant differences with tak-
ing medicines or diet before and after treatment,
whereas metformin further increased frequency of
menstruation. Paradisi et al. reported that flu-
tamide therapy showed a significant enhancement
in the percentage of ovulation cycles and regulat-
ed the menstrual profile in their PCOS patients.
Also, Gambineri reported that metformin further
increased frequency of menstruation compared
with placebo after 6 months (18, 32). This differ-
ence is probably related to higher BMI of their
patients. Maybe, by dividing our patients’ men-
struation pattern to regular and irregular, further
beneficial findings could be offered. Well de-
designed clinical trials on the current topic are there-
fore recommended, especially use of flutamide
and metformin and also hypocaloric diet and de-
termining their effect on clinical and biochemi-
cal characteristics of PCOS versus non PCOS pa-
tients can be an important area for investigation.

Lifestyle modification is strongly suggested for
the treatment of overweight-obese PCOS women.
It causes improvement in their general health and
prevents long term consequences. Also, different
beneficial treatment options according to our de-
sired outcomes in the diet of overweight/obese
PCOS women would help the experts to plan and
treat patients according to each of their profile
disturbance (any of the 4 groups). Considering the
beneficial effects of hypocaloric diet compared
to the medicine, life style and nutrition modifica-
tion in PCOS patients was also effective in our
study. Of course, considering findings about met-
formin and flutamide versus diet alone, it is sup-
posed that our conclusions should be considered
with caution and judiciously and they require
more attention before clinical recommendations.

Conclusion
The most obvious finding of this study is that the
use of metformin and flutamide improves and ac-
celerates normalizing the anthropometric indices
and laboratory tests in obese/overweight PCOS
women under hypocaloric diet.

Conflict of Interest
The authors declare no conflict of interest.

References
1. March WA, Moore VM, Willson KJ, Phillips DI,
Norman RJ, Davies MJ. The prevalence of polycys-
tic ovary syndrome in a community sample assessed
under contrasting diagnostic criteria. Hum Reprod.
3. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L,
Wang P. Continuing metformin throughout preg-
nancy in women with polycystic ovary syndrome
appears to safely reduce first-trimester spontaneous
4. Stamets K, Taylor DS, Kunselman A, Demers LM,
Pelkman CL, Legro RS. A randomized trial of the
effects of two types of short-term hypocaloric diets
on weight loss in women with polycystic ovary syn-
5. Hoeger KM, Kochman L, Wixom N, Craig K, Mill-
er RK, Guzick DS. A randomized, 48-week, place-


25. Glazer NL, Hendrickson AF, Schellenbaum GD, Mueller BA. Weight change and the risk of gesta-


